POINT Bio Shares Jump After Updated Data From Prostate Cancer Candidate

 

• POINT Biopharma Global Inc 
  PNT+21.1%+ Free Alerts
   shared updated efficacy and safety data from the 27-patient lead-in cohort for the Company's phase 3 SPLASH trial evaluating PNT2002 for metastatic castration-resistant prostate cancer (mCRPC). 
• The newly released data based on a median follow-up of 11.7 months revealed a median radiographic progression-free survival (rPFS) of 11.5 months, compared to the control arm benchmarks of 3.5–4.2 months.
• Median overall survival had not been reached with an 11.7-month median duration of follow-up from the time of enrollment.
• A best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with the evaluable disease at baseline.
• From a median baseline PSA (ng/mL) of 22 (range 0.3–701.0), 11 (42%) participants achieved a PSA50 response.
• PNT2002 was well tolerated, with no treatment-related deaths and few treatment-related AEs of grade 3 or higher.

https://www.benzinga.com/general/biotech/22/09/28832998/point-biopharma-shares-jump-after-updated-efficacy-safety-data-from-prostate-cancer-candidate